Prostate Cancer Clinical Trial
A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy
|Source||M.D. Anderson Cancer Center|
|Contact||Sumit K. Subudhi, MD, PHD|
|Start date||June 7, 2017|
|Completion date||June 2019|
The goal of this clinical research study is to learn about the safety and tolerability of
giving Darzalex (daratumumab) to patients who have prostate cancer before having an
already-scheduled prostatectomy (surgical removal of the prostate).
Researchers also want to learn if daratumumab can help to control the disease before the prostatectomy.
Study Drug Administration:
If participant is found to be eligible to take part in this study, participant will receive daratumumab 1 time each week for 4 weeks before participant's prostatectomy. During Week 1, participant's dose of daratumumab will be given over 8 hours. After that, each dose will be given over about 4 hours.
Length of Study:
Participant may receive up to 4 doses of daratumumab. Participant will no longer be able to take the study drug if the disease gets worse, if intolerable side effects occur, or if participant is unable to follow study directions.
Participation on the study will be over after the Week 18 visit (described below).
During Weeks 1-4:
- Participant will have a physical exam
- Blood (about 2 tablespoons) will be drawn for routine and blood type testing.
- During Week 3 only, blood (about 1-2 teaspoons) will be drawn to check participant's PSA levels.
During Week 6 (the week of participant's surgery):
- Participant will have a physical exam
- Blood (about 2 tablespoons) will be drawn for routine tests, including measurements of participant's PSA and testosterone levels. Part of this sample will also be used for blood type testing. Daratumumab treatment will interfere with blood type testing which is needed before blood transfusions can be given. For this reason, a test to find out participant's blood type will be performed before participant receives daratumumab. Participant should carry the blood type card with participant while participant is on this study.
- Participant will have surgery to remove participant's prostate. Participant will sign a separate consent form explaining the procedure and its risks in more detail.
During Week 18, blood (about 2 tablespoons) will be drawn for routine tests, including measurements of participant's PSA and testosterone levels.
If participant withdrew from the study before Week 18, the study staff may call participant to ask how participant is doing. This call should last about 5-10 minutes.
This is an investigational study. Daratumumab is FDA approved and commercially available to treat multiple myeloma. It is considered investigational to use daratumumab in patients with prostate cancer.
The study doctor can explain how the study drug is designed to work.
Up to 15 participants will be enrolled in this study. All will take part at MD Anderson.
|Recruiting||NCT03177759 - Living With Prostate Cancer (LPC)||N/A|
|Completed||NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data||N/A|
|Not yet recruiting||NCT03160365 - Innovative Planning and Guidance System for Prostate Focal Brachytherapy||N/A|
|Active, not recruiting||NCT02124668 - A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy||Phase 2|
|Completed||NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis||N/A|
|Active, not recruiting||NCT00779168 - White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy||Phase 1|
|Recruiting||NCT01990196 - Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer||Phase 2|
|Recruiting||NCT02766543 - Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer||Phase 2|
|Not yet recruiting||NCT03157947 - Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer||N/A|
|Recruiting||NCT02766686 - Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons||N/A|
|Recruiting||NCT02919111 - Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients||Phase 2/Phase 3|
|Recruiting||NCT02911922 - Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer||N/A|
|Recruiting||NCT02543255 - Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)||Phase 2|
|Recruiting||NCT02916537 - A Phase 1 Trial for Safety and Imaging Evaluation of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA)||Phase 1|
|Recruiting||NCT02886598 - Safety and Efficacy of Firmagon® (Degarelix) for Injection||N/A|
|Recruiting||NCT02747342 - A Phase 1 Trial of SHR3680 in Prostate Cancer as Monotherapy||Phase 1|
|Recruiting||NCT02906241 - PACCT: Partnering Around Cancer Clinical Trials||N/A|
|Recruiting||NCT02917161 - Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study||N/A|
|Recruiting||NCT02918357 - Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence||Phase 2/Phase 3|
|Enrolling by invitation||NCT02840552 - The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer||Phase 3|